Literature DB >> 8167329

Treatment and prevention of cytomegalovirus pneumonia after bone marrow transplantation: where do we stand?

S J Forman1, J A Zaia.   

Abstract

Entities:  

Mesh：

Year:  1994        PMID： 8167329

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  14 in total

1.  Control of cytomegalovirus in bone marrow transplantation chimeras lacking the prevailing antigen-presenting molecule in recipient tissues rests primarily on recipient-derived CD8 T cells.

Authors:  M Alterio de Goss; R Holtappels; H P Steffens; J Podlech; P Angele; L Dreher; D Thomas; M J Reddehase
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

2.  Preemptive CD8 T-cell immunotherapy of acute cytomegalovirus infection prevents lethal disease, limits the burden of latent viral genomes, and reduces the risk of virus recurrence.

Authors:  H P Steffens; S Kurz; R Holtappels; M J Reddehase
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

3.  Evaluation of a quantitative plasma PCR plate assay for detecting cytomegalovirus infection in marrow transplant recipients.

Authors:  G M Gallez-Hawkins; B R Tegtmeier; A ter Veer; J C Niland; S J Forman; J A Zaia
Journal:  J Clin Microbiol       Date:  1997-03       Impact factor: 5.948

4.  Human cytomegalovirus infection up-regulates interleukin-8 gene expression and stimulates neutrophil transendothelial migration.

Authors:  J L Craigen; K L Yong; N J Jordan; L P MacCormac; J Westwick; A N Akbar; J E Grundy
Journal:  Immunology       Date:  1997-09       Impact factor: 7.397

5.  Bone marrow failure by cytomegalovirus is associated with an in vivo deficiency in the expression of essential stromal hemopoietin genes.

Authors:  A Mayer; J Podlech; S Kurz; H P Steffens; S Maiberger; K Thalmeier; P Angele; L Dreher; M J Reddehase
Journal:  J Virol       Date:  1997-06       Impact factor: 5.103

6.  Initial low-dose valganciclovir as a preemptive therapy is effective for cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients.

Authors:  Katsuto Takenaka; Koji Nagafuji; Ken Takase; Tomohiko Kamimura; Yasuo Mori; Yoshikiyo Ito; Yukiko Nishi; Hideho Henzan; Koji Kato; Naoki Harada; Tetsuya Eto; Toshihiro Miyamoto; Takanori Teshima; Koichi Akashi
Journal:  Int J Hematol       Date:  2012-05-01       Impact factor: 2.490

7.  A pharmacodynamic model of ganciclovir antiviral effect and toxicity for lymphoblastoid cells suggests a new dosing regimen to treat cytomegalovirus infection.

Authors:  Audrey Janoly-Dumenil; Isabelle Rouvet; Nathalie Bleyzac; Florence Morfin; Marie-Therese Zabot; Michel Tod
Journal:  Antimicrob Agents Chemother       Date:  2012-04-23       Impact factor: 5.191

8.  Oral valganciclovir as preemptive therapy is effective for cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients.

Authors:  Katsuto Takenaka; Tetsuya Eto; Koji Nagafuji; Kenjiro Kamezaki; Yayoi Matsuo; Goichi Yoshimoto; Naoki Harada; Maki Yoshida; Hideho Henzan; Ken Takase; Toshihiro Miyamoto; Koichi Akashi; Mine Harada; Takanori Teshima
Journal:  Int J Hematol       Date:  2009-01-17       Impact factor: 2.490

9.  Heterogeneous impact of cytomegalovirus reactivation on nonrelapse mortality in hematopoietic stem cell transplantation.

Authors:  Satoshi Kaito; Yujiro Nakajima; Konan Hara; Takashi Toya; Tetsuya Nishida; Naoyuki Uchida; Junichi Mukae; Takahiro Fukuda; Yukiyasu Ozawa; Masatsugu Tanaka; Kazuhiro Ikegame; Yuta Katayama; Takuro Kuriyama; Junya Kanda; Yoshiko Atsuta; Masao Ogata; Ayumi Taguchi; Kazuteru Ohashi
Journal:  Blood Adv       Date:  2020-03-24

Review 10.  CMV in Hematopoietic Stem Cell Transplantation.

Authors:  Rafael de la Cámara
Journal:  Mediterr J Hematol Infect Dis       Date:  2016-06-20       Impact factor: 2.576
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.